IGFBP5 and metabolic dysfunction-associated steatotic liver disease: The concentration of IGFBP5 in serum from NAFLD patients is positively correlated with fibrosis and steatosis in the liver and has been proposed to be a marker for progression from NAFLD to a more serious liver disease, non-alcoholic steatohepatitis (NASH) (57).